Authors
Chuprov A.D., Kazennov A.N., Kazennova I.A.
Orenburg branch of S. Fyodorov Eye Microsurgery Federal State Institution, Orenburg
Abstract
Background: the available literature data on the efficacy of the Ahmed valve system implantation for neovascular glaucoma treatment reflect inconsistently the complications and long-term effects of this procedure.
Aim: to evaluate the efficacy of the Ahmed system valve in patients with secondary neovascular glaucoma.
Material and methods: during the study, medical records of patients with neovascular glaucoma (n = 50) who underwent implantation of the Ahmed valve (model FP8, USA) were reviewed. The postoperative follow-up period was 12 months. Patients were examined by clinical and ophthalmological methods before and after surgery, including refractometry, tonometry, perimetry and optical coherence tomography of the eye.
Results: the visual acuity of the study participants before surgery ranged from 0 to 0.3, after surgery — from 0 to 0.4. The boundaries of the peripheral visual fields after valve implantation expanded by an average of 15±2.1° (37.5% of cases). There was a significant decrease in IOP 1 year after surgery compared with initial meaning (p<0.05). Ahmed valve implantation was successful in all cases without intraoperative complications. In the postoperative period, the appearance of hyphema (in 13% of patients), iridocyclitis (3%) and choroid detachment (9%) were noted.
Conclusion: Ahmed valve system creates a stable hypotensive effect in neovascular glaucoma in 82.3% of cases within 1 year after surgery, stops the progression of the glaucomatous process, eliminates discomfort and pain in patients.
Keywords: neovascular glaucoma; Ahmed valve; intraocular pressure, postoperative complications.
References
1. Tham Y.C., Li X., Wong T.Y. et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014; 121: 2081-2090.
2. Xie Zh., Liu H., Du M. et al. Efficacy of Ahmed glaucoma valve implantation on neovascular glaucoma. Int. J. Med. Sci. 2019; 16: 1371-1376.
3. Hayreh S.S. Neovascular glaucoma. Prog Retin Eye Res. 2007; 26: 470-485.
4. SooHoo J.R., Seibold L.K., Kahook M.Y. Recent advances in the management of neovascular glaucoma. Semin Ophthalmol. 2013; 28: 165-172.
5. Takihara Y., Inatani M., Fukushima M. et al. Trabeculectomy with mitomycin C for neovascular glaucoma: prognostic factors for surgical failure. Am J Ophthalmol. 2009; 147: 912-918.
6. Netland P.A., Ishida K., Boyle J.W. The Ahmed glaucoma valve in patients with and without neovascular glaucoma. J Glaucoma. 2010;19(9): 581–586.
7. Riva I., Roberti G., Oddone F. et al. Ahmed glaucoma valve implant: surgical technique and complications. Clin Ophthalmol. 2017; 11: 357-367.
8. Sharpe R.A., Kammerdiener L.L., Wannamaker K.W. et al. Comparison of outcomes of resident-performed Ahmed valve implantation vs trabeculectomy. J Curr Glaucoma Pract. 2016; 10(2): 60-67.
9. Evans J.R., Michelessi M., Virgili G. Laser photocoagulation for proliferative diabetic retinopathy. Cochrane Database Syst Rev. 2014: 2014(11): CD011234.
10. Nakatake S., Yoshida S., Nakao S. et al. Hyphema is a risk factor for failure of trabeculectomy in neovascular glaucoma: a retrospective analysis. BMC Ophthalmol. 2014; 14: 55.
